Medizinische Universität Graz - Research portal
Jost Philipp |
Presentations at scientific and public conferences
Balic, M; Klocker, EV; Dobrić, N; Graf, R; Pancheri, L; Suppan, C; Jost, PJ; Heitzer, E; Dandachi, N
High-sensitivity detection and broad genomic profiling in HR+/HER2- breast cancer: Final comparative results using targeted single-gene and broad-panel sequencing assays.
The Journal of Liquid Biopsy Supplement: November 2024. 2024; 5(100190):-6th Annual Congress of Liquid Biopsy: “Advancing and Accelerating Access of Liquid Biopsy” (ISLB 2024); NOV 23-25, 2024; Denver, Colorado, USA.
[Poster]
FullText
Balihodzic, A; Jäger, V; Reinisch, A; Jost, PJ; Strasser, A; Dengler MA
BCL-XL plays a role in determining lung cancer cell fate upon chemotherapy
Doctoral Day of Medical University of Graz; FEB 8, 2024; Graz. 2024.
[Oral Communication]
Dobrić, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients.
Proceedings of the 13th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS). 2024; -13th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS); MAR 4-6, 2024; Graz, AUSTRIA.
[Poster]
Dobrić, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
ctDNA profiling of HR+/HER2-low and HR+/HER2-0 metastatic breast cancer patients.
Molecular Oncology Supplement: EACR 2024: Innovative Cancer Science. 2024; 18(S1):i-ii.-EACR 2024 Congress: Innovative Cancer Science; JUN 10-13, 2024; Rotterdam, THE NETHERLANDS.
[Poster]
FullText
John, N; Terbuch, A; Konjic, S; Absenger, G; Jost, PJ; Lindenmann, J; Fediuk, M; Sassmann, T; Wurm, R; Zacharias, M; Posch, F; Hochmaier, MJ; Fabikan, H; Weinlinger, C; Illini, O; Horvath, L; Gamerith, G; Pircher, A; Brcic, L
Prognostic impact of targetable driver alterations in resected early-stage lung cancer
WIEN KLIN WOCHENSCHR. 2024; 136(S13):S531-S531.-48. Jahrestagung ÖGP - 8th Jahrestagung OGTC; SEP 26-28, 2024; Vienna, Austria.
[Poster]
Web of Science
Jonas, K; Riedl, JM; Steinlechner, SM; Moik, F; Jahn, S; Hasenleitner, S; Doleschal, B; Weiss, L; Seeber, A; Rumpold, H; Winder, T; Greil, R; Höfler, G; Gerger, A; Jost, P; Heitzer, E;
Low-level variants present a challenge in the clinical interpretation of liquid-biopsy-based comprehensive genomic profiling for patients with solid tumors
EACR Liquid Biopsies Conference; NOV 12-14, 2024; Lyon, FRANCE. 2024.
[Oral Communication]
Klocker, EV; Dobrić, N; Suppan, C; Graf, R; Foldi, J; Heitzer, E; Oesterreich, S; Lee, AV; Jost, PJ; Dandachi, N; Balic, M
Comparison of lobular vs NST hormone receptor-positive
metastatic breast cancer patients in early lines of treatment via
comprehensive genomic profiling and whole-genome sequencing of
circulating tumor DNA.
Proceedings of the San Antonio Breast Cancer Symposium 2024; Abstract Number: SESS-1277
. 2024; -San Antonio Breast Cancer Symposium 2024; DEC 10-13, 2024; San Antonio, TX; USA.
[Poster]
FullText
Moik, F; Riedl, JM; Edlinger, L; Esterl, T; Hasenleithner, S; Kostmann, S; Cebular, L; Jahn, S; Kashofer, K; Zacharias, M; Hoefler, G; Heitzer, E; Gerger, A; Jost, PJ
Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
ANN ONCOL. 2024; 35: S262-S263.
Doi: 10.1016/j.annonc.2024.08.130
Web of Science
FullText
FullText_MUG
Moik, F; Riedl, JM; Edlinger, L; Esterl, T; Hasenleithner, S; Kostmann, S; Cebular, L; Jahn, S; Kashofer, K; Zacharias, M; Hoefler, G; Heitzer, E; Gerger, A; Jost, PJ
122P - Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
Annals of Oncology. Abstract Book of the ESMO Congress 2024, 13-17 September 2024. . 2024; 35(S2):262-263.-ESMO 2024; SEP 13-17, 2024; Barcelona, Spain.
[Poster]
FullText
Seeber, A; Huemer, F; Doleschal, B; Taghizadeh, H; Reimann, P; Moik, F; Kostmann, S; Wagner, L; Granitzer, J; Hamid, MA; Bachleitner, C; Amann, A; Wolf, D; Greil, R; Jost, PJ; Winder, T; Rumpold, H; Weiss, L; Gerger, A; Riedl, JM
Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
ANN ONCOL. 2024; 35: S445-S446.
Doi: 10.1016/j.annonc.2024.08.599
Web of Science
FullText
FullText_MUG
Seeber, A; Huemer, F; Doleschal, B; Taghizadeh, H; Reimann, P; Moik, F; Kostmann, S; Wagner, L; Granitzer, L; Abdel Hamid, M; Bachleitner, C; Amann, A; Wolf, D; Greil, R; Jost, PJ; Winder, T; Rumpold, H; Weiss, L; Gerger, A; Riedl, JM
530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Annals of Oncology. Abstract Book of the ESMO Congress 2024, 13-17 September 2024. . 2024; 35(S2):445-446.-ESMO 2024; SEP 13-17, 2024; Barcelona, Spain.
[Poster]
FullText
Siebenhofer-Kroitzsch, A; Kornhäusl, K; Fitzek, M; Jost, PJ; Kastner, P
Onkologie: Auf neuen Pfaden zur besten (Mit-) Versorgung
Austrian Health Forum (AHF) Schladming; MAY 23-25, 2024; Schladming, AUSTRIA. 2024.
[Science to Public]
Siegerist, F; Schnoeder, TM; Jayavelu, AK; Perner, F; Jost, P; Hammer, E; Voelker, U; Lopez-Cayuqueo, K; Schmidt-Ott, K; Buttner-Herold, M; Endlich, N; Heidel, FH
Chronic Kidney Dysfunction Induced By Jak2V617F-Mediated Mesangiolysis
BLOOD. 2024; 144: 3147-3148.
Doi: 10.1182/blood-2024-205670
Web of Science
FullText
FullText_MUG
Balihodzic, A; Fernandez Hernandez, FJ; Jäger, V; Vosberg, S; Schnur, T; Kainz, G; Gallé, B; Schweintzger, N; Kühberger, S; Heitzer, E; Reinisch, A; Jost, PJ; Pichler, M; Dengler, MA
Application of genome-wide CRISPR/Cas9 screen to identify synthetic lethality with MCL-1 inhibition in lung cancer.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2023; 16: 1-28.-OeGHO- & AHOP-Frühjahrstagung 2023; März 30-April 1, 2023; Innsbruck, AUSTRIA.
[Oral Communication]
FullText
Balihodzic, A; Fernandez-Hernandez, FJ; Jäger, V; Vosberg, S; Tonietto, M; Schnur, T; Kainz, G; Gallé, B; Schweintzger, N; Kühberger, S; Heitzer, E; Reinisch, A; Jost, PJ; Pichler, M; Dengler, MA
Application of genome-wide CRISPR/Cas9 screen to identify synthetic lethality with MCL-1 inhibition in lung cancer
Doctoral Day of Medical University of Graz; FEB 9, 2023; Graz, AUSTRIA. 2023.
[Poster]
Barth, D; Moik, F; Steinlechner, SM; Posch, F; Schlintl, V; Koch, L; John, N; Wurm, R; Pichler, M; Bauernhofer, T; Reimann, P; Wohlkönig, C; Richtig, E; Winder, T; Preusser, M; Jost, PJ; Ay, C; Gerger, A; Terbuch, A; Riedl, JM
Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
ANN ONCOL. 2023; 34: S259-S259.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Barcelona, SPAIN.
Doi: 10.1016/j.annonc.2023.09.2917
[Poster]
Web of Science
FullText
FullText_MUG
Dandachi, N; Graf, R; Pancheri, L; Dobric, N; Klocker, EV; Suppan, C; Jost, PJ; Heitzer, E; Balic, M
A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2-breast cancer patients
ANN ONCOL. 2023; 34: S1162-S1163.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Madrid, SPAIN.
Doi: 10.1016/j.annonc.2023.09.1289
[Poster]
Web of Science
FullText
FullText_MUG
Dandachi, N; Graf, R; Pancheri, L; Dobric, N; Klocker, EV; Suppan, C; Jost, PJ; Heitzer, E; Balic, M
Sensitive detection of circulating tumor DNA using targeted capture sequencing in advanced HR+/HER2- breast cancer patients.
6th ACTC - Advances in Circulating Tumor Cells Book of Abstracts. 2023; -6th ACTC - Advances in Circulating Tumor Cells; SEP 20-23, 2023; Skiathos, GREECE.
[Poster]
FullText
Dill, V; Kirmes, K; Klug, M; Herhaus, P; Ruland, J; Bassermann, F; Götze, KS; Jilg, S; Jost, PJ; Bongiovanni, D
Detection of dysregulated prothrombotic pathways by platelet mass cytometry in patients with essential thrombocythemia
ONCOL RES TREAT. 2023; 46: 222-222.
[Poster]
Web of Science
Dobric, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
ANN ONCOL. 2023; 34: S387-S387.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Madrid, SPAIN.
Doi: 10.1016/j.annonc.2023.09.667
[Poster]
Web of Science
FullText
FullText_MUG
Dobric, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M.
Comparison of ctDNA fraction and mutational profiles of plasma samples of HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
6th ACTC - Advances in Circulating Tumor Cells Book of Abstracts. 2023; -6th ACTC - Advances in Circulating Tumor Cells; SEP 20-23, 2023; Skiathos, GREECE.
[Poster]
FullText
Jäger, V; Flasch, B; Vosberg, S; Fernandez-Hernandez, F; Balihodzic, A; Kienreich, S; Stanzer, S; Herold, M; Kargl, J; Dengler, M; Jost, P
Uncovering innovative molecular targets for lung cancer therapy on the highly recurrent chromosomal gain of 1q21
OeGHO- & AHOP-Frühjahrstagung 2023; Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 30-APR 1; Innsbruck, Austria. 2023.
[Poster]
FullText
Jäger, V; Flasch, B; Vosberg, S; Fernandez-Hernandez, F; Balihodzic, A; Kienreich, S; Stanzer, S; Herold, M; Kargl, J; Dengler, M; Jost, P
Uncovering innovative molecular targets for lung cancer therapy on the highly recurrent chromosomal gain of 1q21
Doctoral Day of Medical University of Graz; FEB 9; Graz, AUSTRIA. 2023.
[Poster]
Jäger, V; Flasch, B; Vosberg, S; Fernandez-Hernandez, F; Tonietto M; Balihodzic, A; Kienreich, S; Stanzer, S; Herold, M; Kindler, O; Maitz, K; Kargl, J; Dengler, M; Jost, P
Oncogene or tumor-suppressor? - Functional characterization of the plasma membrane rupture mediator Ninjurin 1 in lung cancer
13th Scientific Retreat of the DK-MCD; SEP 25-27; Seggau, AUSTRIA. 2023.
[Oral Communication]
Koschmieder, S; Isfort, S; Teichmann, LL; Schafhausen, P; Heidel, F; Hochhaus, A; Griesshammer, M; Sockel, K; Jost, P; Wolleschak, D; Döhner, K; Goethert, JR; Radsak, MP; Augustin, M; Becker, H; Giagounidis, A; Schaich, M; Klausmann, M; Von Bubnoff, N; Stegelmann, F; Kortmann, M; Frank, J; Hellmich, M; Brümmendorf, TH
Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
BLOOD. 2023; 142:
Doi: 10.1182/blood-2023-173225
Web of Science
FullText
FullText_MUG
Lorch, M; Pfirrmann, M; Fabisch, C; Oberle, L; Kohn, D; Kohlbrenner, K; Brümmendorf, TH; Burchert, A; Krause, SW; le Coutre, P; Hänel, M; Franke, GN; Stegelmann, F; Radsak, MP; Kunzmann, ; Jost, PJ; Baerlocher, GM; Mayer, J; Hofmann, WK; Hochhaus, A; Saussele, S
Health-related quality of life (HRQoL) effects of pegylated Interferon α2b (PEG-IFN) in Nilotinib (NIL)-based treatment of chronic myeloid leukemia (CML)
ONCOL RES TREAT. 2023; 46: 279-280.
[Poster]
Web of Science
Riedl, JM; Steinlechner, SM; Moik, F; Heitzer, E; Jahn, S; Hasenleithner, S; Doleschal, B; Weiss, L; Seeber, A; Rumpold, H; Winder, T; Greil, R; Jost, PJ; Hoefler, G; Speicher, M; Gerger, A
SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvagetherapy matching in patients with advanced and refractory carcinoma
ANN ONCOL. 2023; 34: S1186-S1186.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Barcelona, SPAIN.
Doi: 10.1016/j.annonc.2023.09.1349
[Poster]
Web of Science
FullText
FullText_MUG
Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; McGranahan, N; Jost, P
Inflammatory cell death acts as tumor suppressor in lung adenocarcinoma
INTERNIST. 2022; 63(SUPPL 3):338-339.
[Oral Communication]
Web of Science
Balihodzic, A; Prinz, F; Jonas, K; Barth, DA; Dengler, MA; Slaby, O; Jost, PJ; Klec, C; Pichler, M
A novel long non-coding RNA hypoxia associated-lncRNA1 is involved in cellular growth, apoptosis and patients’ prognosis in clear cell renal cell carcinoma.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2022; 15: 37-67.-OeGHO- & AHOP-Frühjahrstagung; APRIL 8-10, 2022; Graz, AUSTRIA.
[Poster]
FullText
Balihodzic, A; Prinz, F; Jonas, K; Barth, DA; Dengler, MA; Slaby, O; Jost, PJ; Klec, C; Pichler, M.
A novel long non-coding RNA hypoxia associated-lncRNA1 is involved in cellular growth, apoptosis and patients’ prognosis in clear cell renal cell carcinoma
8. International Student Congress Graz; JUNE 16-18, 2022; Graz, AUSTRIA. 2022.
[Poster]
Barth, D; Stradner, M; Hutterer, H; Spiegelberg, J; Bauernhofer, T; Absenger, G; Jost, P; Pichler, M
Blood-based B-cell subtypes as predictors of treatment response during treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2022. 2022; -OeGHO Frühjahrstagung 2022; APR 8-10, 2022; Graz, AUSTRIA.
[Poster]
Brcic, L; Zacharias, M; Konjic, S; Kashofer, K; Absenger, G; Jost, PJ; Wurm, R; Lindenmann, J; Terbuch, A
Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A singlecenter experience
ANN ONCOL. 2022; 38(9): S1557-S1557.
Doi: 10.1016/j.annonc.2022.10.344
[Poster]
Web of Science
FullText
FullText_MUG
Gerger, A; Riedl, J; Hasenleithner, SO; Höfler, G; Jahn, S; Esterl, T; Jost, PJ; Speicher, MR; Heitzer, E.
Identifizierung von Tumorprädispositionen im Rahmen von klinischen ctDNA-Tests
ÖGH Jahrestagung; Sep 29, 2022; Graz, AUSTRIA. 2022.
[Oral Communication]
Huemer, M; Jahn-Kuch D; Hofmann, G; Andritsch, E; Farkas C; Schaupp, W; Masel EK; Jost JP; Pichler M
Trends of public interest in palliative care, euthanasia, and advanced health care directives in Austria, Germany, and Switzerland using big data from Google
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2022; 22(3):17-17.-OeGHO & AHOP Frühjahrstagung; APR 8-10, 2022; Graz, AUSTRIA.
[Poster]
FullText
Keller, EC; Jost, PJ; Schwamborn, K; Weichert, W; Horn, T; Slotta-Huspenina, J
Mixed Lineage Kinase Domain-like Protein (MLKL) in Primary Resected Bladder Cancer: Expression, Prognostic Role and Correlations with the Immune Environment
MODERN PATHOL. 2022; 35(SUPPL 2): 613-613.
[Poster]
Web of Science
Keller, EC; Jost, PJ; Schwamborn, K; Weichert, W; Horn, T; Slotta-Huspenina, J
Mixed Lineage Kinase Domain-like Protein (MLKL) in Primary Resected Bladder Cancer: Expression, Prognostic Role and Correlations with the Immune Environment
LAB INVEST. 2022; 102(SUPPL 1): 613-613.
[Poster]
Web of Science
Krajina, K; Kapeller, A; Dengler, M; Jost, P; Pichler, M; Klec, C
The long non-coding RNA NORAD and its relevance on PARP inhibitor sensitivity in triple negative breast cancer
Proceedings of the Annual Meeting of the Austrian Society
of Haematology and Medical Oncology. 2022; -OeGHO- & AHOP-Frühjahrstagung 2022; APR 8-10, 2022; Graz, AUSTRIA.
[Poster]
Lindenmann, J; Fink-Neuboeck, N; Fediuk, M; Porubsky, Ch; Absenger, G; Mykoliuk, I; Brcic, L; Anegg, U; Maier, A; Jost, P; Smolle, J; Smolle-Juettner, FM
Recurrence and survival following surgery of T3 esophageal carcinoma with curative intent. Role of circumferential resection margin.
European Surgrey- ACA. 2022; 54: 50-50.-63. Österreichischer Chirurgenkongress; JUN 15-17, 2022; Graz, AUSTRIA.
[Oral Communication]
Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C
Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251.
Doi: 10.1182/blood-2022-160087
[Oral Communication]
Web of Science
FullText
FullText_MUG
Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
Schranz, A; Sternad, C; Mischinger, HJ; Wagner, D; Jost, PJ; Riedl, J; Wolfler, A; Pieber, T; Sourij, H; Aberer, F
Incidence of diabetes and its impact on survival after pancreatic tumor surgery - a retrospective data analysis
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 4):258-259.-Jahrestagung der Österreichischen Diabetesgesellschaft ;
[Poster]
Web of Science
Zacharias, M; Konjic, S; Absenger, G; Hochmair, MJ; Fabikan, H; Weinlinger, C; Illini, O; Jost, PJ; Schlintl, V; Wurm, R; Lindenmann, J; Fediuk, M; Brcic, L; Terbuch, A
Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
J THORAC ONCOL. 2022; 17(9): S201-S202.
[Poster]
Web of Science
Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; Branca, C; McGranahan, N; Jost, PJ
RIPK3 downregulation in lung cancer alters the tumor immune micro-environment supporting tumor progression
ONCOL RES TREAT. 2021; 44: 51-52.
Web of Science
Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; McGranahan, N; Jost, PJ
Necroptosis establishes an inflammatory tumor immune microenvironment acting as tumor suppressor in lung adenocarcinoma
ANN ONCOL. 2021; 32: S945-S945.
Doi: 10.1016/j.annonc.2021.08.1788
[Poster]
Web of Science
FullText
FullText_MUG
Dill, V; Wagner, C; Keller, E; Shoumariyeh, K; Odinius, T; Buschhorn, L; Suren, C; Hecker, J; Herhaus, P; Sandherr, M; Schmidt, B; Slotta-Huspenina, J; Bassermann, F; Hockendorf, U; Branca, C; Jilg, S; Jost, PJ
RIPK3-dependent necroinflammation as a disease promoting mechanism in human myelofibrosis
ONCOL RES TREAT. 2021; 44: 161-161.
Web of Science
Jäger, V; Jost, P; Dengler, M
Molecular mechanisms of transformtion in lung cancer
11th Scientific Retreat of the DK-MCD; SEP 27-29, 2021; Seggau; AUSTRIA. 2021.
[Oral Communication]
Jost, PJ; Munkhbaatar, E; Dietzen, M; Branca, C; McGranahan, N
Clonal evolution in lung cancer highlights MCL-1 gains as therapeutic target in lung adenocarcinoma
J THORAC ONCOL. 2021; 16(4):S704-S704.
[Poster]
Web of Science
Klocker, EV; Posch, F; Suppan, C; Mischitz, N; Dengler, L; Steiner, D; Müller, HD; Jost, P; Dandachi, N; Balic, M
Histopathological features and prognosis of early lobular breast cancer
Oncology Research and Treatment, Vol. 44, Suppl. 2, 2021. 2021; -Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie ; OCT 1-4, 2021; Berlin, GERMANY.
[Poster]
Lorch, M; Pfirrmann, M; Fabisch, C; Oberle, L; Kohn, D; Kohlbrenner, K; Brummendorf, TH; Burchert, A; Krause, SW; le Coutre, P; Hanel, M; Franke, GN; Stegelmann, F; Radsak, M; Kunzmann, V; Jost, PJ; Hofmann, WK; Hochhaus, A; Saussele, S
Health-related quality of life (HRQoL) in CML-patients at diagnosis compared to general population
ONCOL RES TREAT. 2021; 44: 71-72.
Web of Science
Smolle, M; Woelfel, J; Acem, I; Van De Sande, MAJ; Jeys, L; Bonekamp, H; Pollock, R; Keller, J; Tunn, PU; Haas, R; Van Ginkel, RJ; Verhoef, C; Posch, F; Liegl-Atzwanger, B; Moustafa-Hubmer, D; Jost, PJ; Leithner, A; Szkandera J
Neoadjuvant and adjuvant radiotherapy decreases the risk of local recurrence and adjuvant chemotherapy improves overall survival in a multicentre cohort of 2184 extremity soft tissue sarcoma patients
CTOS Abstract Book. 2021; -CTOS (Connective Tissue Oncology Society); NOV 10-13; Toronto, CANADA.
[Oral Communication]
Smolle, MA; Woelfel, J; Acem, I; van de Sande, M; Jeys, L; Bonekamp, H; Pollock, R; Keller, J; Tunn, PU; Haas, R; van Ginkel, RJ; Verhoef, C; Posch, F; Liegl-Atzwanger, B; Moustafa-Hubmer, D; Jost, P; Leithner, A; Szkandera, J
Effect of Neoadjuvant and Adjuvant Radiotherapy on Local Recurrence, Distant Metastasis, and Overall Survival in Extremity Soft Tissue Sarcoma.
Abstract Book of the EMSOS 2021. 2021; -EMSOS Annual Meeting 2021; DEC 1-3, 2021; Graz, AUSTRIA.
[Onlinepräsentation]
Terbuch, A; Absenger, G; Steinlechner, S; Jost, P; Wurm, R; Wohlkonig, C; Olschewski, H; Richtig, E; Koch, L; Winder, T; Woll, E; Gerger, A
Autriche - AUsTrian Registry for Immune CHEckpoint inhibitors
ONCOL RES TREAT. 2021; 44: 229-229.
[Poster]
Web of Science
Terbuch, A; Absenger, G; Steinlechner, S; Mayer, M; Jost, P; Wurm, R; Wohlkönig, C; John, N; Olschewski, H; Richtig, E; Koch, L; Winder, T; Wöll, E; Gerger, A;
AUTRICHE – AUsTrian Registry for Immune CHEckpoint inhibitors
Jahrestagung der DGHO; OKT 1-4, 2021; Berlin. 2021.
[Poster]
Munkhbaatar, E; Dietzen, M; McGranahan, N; Jost, PJ
Dissecting clonal evolution in lung adenocarcinoma identified chromosomal gains on 1q21 implying novel therapeutic targets.
ONCOL RES TREAT. 2020; 43(SUPPL 4):135-135.
[Onlinepräsentation]
Web of Science
Horak, P; Heining, C; Kreutzfeldt, S; Heilig, CE; Mohrmann, L; Gieldon, L; Frohlich, M; Uhrig, S; Hubschmann, D; Beck, K; Richter, D; Wolf, S; Pfutze, K; Georg, C; Meissburger, B; Klauschen, F; Ochsenreither, S; Folprecht, G; Siveke, J; Bauer, S; Kindler, T; Brandts, C; Borries, M; von Bubnoff, N; Spiekermann, K; Jost, PJ; Schulze-Osthoff, K; Bitzer, M; Schirmacher, P; von Kalle, C; Schlenk, R; Klink, B; Flutter, B; Weichert, W; Stenzinger, A; Schrock, E; Brors, B; Glimm, H; Frohling, S
Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies: Results from the MASTER trial of the German Cancer Consortium
CANCER RES. 2019; 79(13):
Doi: 10.1158/1538-7445.AM2019-468
Web of Science
FullText
FullText_MUG
Pfarr, N; Boxberg, M; Riedmann, K; Jesinghaus, M; Konukiewitz, B; Glimm, H; Jost, PJ; Frohling, S; Weichert, W
Detection of the mutation burden status and microsatellite instability by targeted next generation sequencing applying a large gene panel
VIRCHOWS ARCH. 2019; 475: S104-S104.
Web of Science
Jilg, S; Hauch, RT; Wahida, A; Kauschinger, J; Buschhorn, L; Odinius, T; Reidel, V; Schmid, B; Hempel, D; Hollein, A; Peschel, C; Bassermann, F; Slotta-Huspenina, J; Hockendorf, U; Jost, PJ
Stage-dependent role of pro-necroptotic RIPK1/3 in patients with MDS and CMML
ONCOL RES TREAT. 2018; 41: 94-94.
Web of Science
Muller, N; Fischer, J; Haas, T; Poeck, H; Yabal, M; Jost, PJ
RIPK3 as an essential mediator of inflammation and cell death which facilitates IL-17 induction in innate and adaptive T lymphocyte subsets
EUR J IMMUNOL. 2018; 48: 121-121.
Web of Science
Pfarr, N; Boxberg, M; Riedmann, K; Jesinghaus, M; Konukiewitz, B; Glimm, H; Jost, PJ; Frohling, S; Weichert, W
Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel
ANN ONCOL. 2018; 29:
Web of Science
Hockendorf, U; Yabal, M; Jost, PJ
RIPK3-Dependent Cell Death and Differentiation of Leukemia Initiating Cells Restrict Myeloid Leukemogenesis
ANN HEMATOL. 2017; 96: S50-S50.
Web of Science
Jilg, S; Kauschinger, J; Hauch, RT; Reidel, V; Muller-Thomas, C; Schmidt, B; Hockendorf, U; Peschel, C; Gotze, KS; Jost, PJ
Inhibition of Polo-like Kinase 1 effectively induces cell death in MDS, CMML-1/-2 and sAML while sparing the healthy heamatopoiesis
ONCOL RES TREAT. 2017; 40: 179-179.
Web of Science
Jilg, S; Reidel, V; Kauschinger, J; Muller-Thomas, C; Hauch, R; Schauwecker, J; Burkhard, S; Hockendorf, U; Peschel, C; Kern, W; Haferlach, T; Slotta-Huspenina, J; Gotze, KS; Jost, PJ
BCL-2 INHIBITION BY ABT-199 POTENTLY INDUCES CELL DEATH IN MDS PROGENITORS DESPITE HIGH-RISK MUTATIONS IN ASXL1, RUNX1, TP53 OR EZH2
LEUKEMIA RES. 2017; 55: S156-S156.
Doi: 10.1016/S0145-2126(17)30385-5
Web of Science
FullText
FullText_MUG
Jost, PJ; Yabal, M; Hockendorf, U
Inflammation and cell death controls AML development, phenotype and outcome
ONCOL RES TREAT. 2017; 40: 54-54.
Web of Science
Rinaldetti, S; Pfirrmann, M; Manz, K; Guilhot, J; Panagiotidis, P; Spiess, B; Seifarth, W; Fabarius, A; Pagoni, M; Dimou, M; Dengler, J; Waller, C; Brummendorf, TH; Herbst, R; Burchert, A; Janssen, C; Goebeler, ME; Jost, PJ; Hanzel, S; Schafhausen, P; Prange-Krex, G; Illmer, T; Janzen, V; Klausmann, M; Eckert, R; Buschel, G; Kiani, A; Hofmann, WK; Mahon, FX; Saussele, S
IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL
HAEMATOLOGICA. 2017; 102: 74-74.
[OPEN ACCESS]
Web of Science
Ahmadova, G; Kreil, S; Jost, PJ; Keller, P; Wolfensberger, N; Maschke, A; Schonberger, B; Haferlach, T; Schwaab, J; Naumann, N; Jahwar, M; Cross, NCP; Fabarius, A; Hofmann, WK; Haferlach, C; Reiter, A; Metzgeroth, G
Clinical characteristics and treatment with tyrosine kinase inhibitors in four patients with ETV6-ABL1 positive eosinophilia-associated myeloproliferative neoplasms
ONCOL RES TREAT. 2016; 39: 232-233.
Web of Science
Glauche, I; Liebscher, H; Baldow, C; Kuhn, M; Schulze, P; Haehnel, T; Voskanyan, A; Guilhot, J; Dulucq, S; von Bubnoff, N; Saussele, S; Mustjoki, S; Jost, PJ; Guilhot, F; Mahon, FX; Roeder, I
A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML
BLOOD. 2016; 128(22):
Doi: 10.1182/blood.V128.22.3099.3099
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Hockendorf, U; Monica, Y; Peschel, C; Jost, PJ
Evasion of Necroptosis and Inflammasome Activation Promotes Myeloid Leukemogenesis
BLOOD. 2016; 128(22):
Doi: 10.1182/blood.V128.22.2856.2856
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Jilg, S; Kauschinger, J; Reidel, V; Muller-Thomas, C; Hauch, R; Schauwecker, J; Schmidt, B; Hockendorf, U; Peschel, C; Gotze, K; Jost, PJ
Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure
BLOOD. 2016; 128(22):
Doi: 10.1182/blood.V128.22.4297.4297
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Reiter, A; Ahmadova, G; Jawhar, M; Virchis, A; Somervaille, T; Williams, M; Schonberger, B; Frewin, R; Jost, PJ; Maschke, A; Keller, P; Haferlach, T; Naumann, N; Schwaab, J; Fabarius, A; Hofmann, WK; Haferlach, C; Cross, NCP; Metzgeroth, G
Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms
BLOOD. 2016; 128(22):
Doi: 10.1182/blood.V128.22.3114.3114
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Saussele, S; Mahon, FX; Guilhot, J; Dengler, J; Waller, CT; Brummendorf, TH; Herbst, R; Burchert, A; Goebeler, ME; Freunek, G; Prummer, O; Jost, PJ; Prange-Krex, G; Illmer, T; Janzen, V; Schafhausen, P; Klausmann, M; Kiani, A; Eckert, R; de Wit, M; Janssen, C; Muller, MC; Hochhaus, A; Richter, J; Pfirrmann, M
Stopping tyrosine kinase inhibitors in a large cohort of European chronic myeloid leukemia (CML) patients: results of the EURO-SKI trial
ONCOL RES TREAT. 2016; 39: 209-209.
Web of Science
Jilg, S; Reidel, V; Muller-Thomas, C; Hockendorf, U; Huberle, C; Peschel, C; Oostendorp, RA; Gotze, KS; Jost, PJ
MCL-1 conveys resistance to ABT-199 in primary MDS samples
ONCOL RES TREAT. 2015; 38: 260-260.
Web of Science
Tweedell, RE; Bergmann-Leitner, ES; Tao, DY; King, JG; Robinson, TM; Bingham, K; Lanar, DE; Jost, PJ; Boddey, JA; Dinglasan, RR
OPTIMIZED PLASMODIUM FALCIPARUM HEPATOCYTE INFECTION MODEL FACILITATES DRUG AND VACCINE DEVELOPMENT
AM J TROP MED HYG. 2015; 93(4): 290-290.
Web of Science
Jost, PJ; Yabal, M; Adler, H; Knies, N; Gross, C; Damgaard, RB; Kanegane, H; Peschel, C; Strasser, A; Gross, O; Ruland, J; Gyrd-Hansen, M
A Mouse Model for XLP-2 Disease Uncovers a Critical Function for IL-1beta and TNF in Driving Hyper-Inflammation
BLOOD. 2014; 124(21):
Web of Science
Yabal, M; Muller, N; Adler, H; Knies, N; Gross, CJ; Damgaard, RB; Kanegane, H; Ringelhan, M; Kaufmann, T; Heikenwalder, M; Strasser, A; Gross, O; Ruland, J; Peschel, C; Gyrd-Hansen, M; Jost, PJ
Aberrant TNF signalling in dendritic cells in the absence of XIAP contributes to X-linked lymphoproliferative disease (XLP-2) by exaggerated necroptosis
ONCOL RES TREAT. 2014; 37: 246-246.
Web of Science
Jilg, S; Konig, J; Hockendorf, U; Schauwecker, J; Huberle, C; Muller-Thomas, C; Schmidt, B; Burgkart, R; Gotze, K; Kolb, HJ; Peschel, C; Jost, PJ
Resistance to apoptosis in high-risk myelodysplastic syndrome can be overcome by pro-apoptotic drug treatment using ABT-737
LEUKEMIA RES. 2013; 37: S29-S30.
Doi: 10.1016/S0145-2126(13)70065-1
Web of Science
FullText
FullText_MUG
Jilg, S; Konig, J; Hockendorf, U; Schauwecker, J; Huberle, C; Muller-Thomas, C; Schmidt, B; Burgkart, R; Kolb, HJ; Gotze, K; Peschel, C; Jost, PJ
Pharmacologic intervention with the pro-apoptotic compound ABT-737 potently induces apoptosis in high-risk MDS/sAML bone marrow cells
ONKOLOGIE. 2013; 36: 124-125.
Web of Science
Jost, PJ; Spinner, S; Kelly, G; Herold, M; Yabal, M; Strasser, A; Peschel, C
The role of the anti-apoptotic Bcl-2 proteins Bcl-x(L) and Mcl-1 in survival of T-cell Non-Hodgkin's lymphoma
ONKOLOGIE. 2012; 35: 4-4.
Web of Science
Yabal, M; Damgaard, RB; Nachbur, U; Ruland, J; Peschel, C; Strasser, A; Silke, J; Gyrd-Hansen, M; Jost, PJ
Inhibition of NOD2 signalling by mutations in the RING domain of XIAP contribute to development of X-linked lymphoproliferative syndrome
ONKOLOGIE. 2011; 34: 113-113.
Web of Science
Jost, PJ; Nachbur, U; Grabow, S; Huang, DC; Bouillet, P; Silke, J; Strasser, A; Kaufmann, T
Anti-cancer SMAC-mimetic compounds accelerate hepatocyte cell death upon FAS or TNF-alpha signalling
ONKOLOGIE. 2010; 33: 63-64.
Web of Science
Jost, PJ; Ferch, U; Weiss, S; Leeder, S; Gross, O; Mak, TW; Peschel, C; Ruland, J
Functional and molecular analysis of maturation of thymocytes in Bcl10 or Malt1 deficient mice.
BLOOD. 2005; 106(11): 929A-929A.
Web of Science